Comparison of pembrolizumab dosing regimens and incidence and severity of immune-related adverse effects: A retrospective, case-control study

Key Points

• The research aims to compare the incidence and severity of immune-related adverse effects (irAEs) between two pembrolizumab dosing regimens.
• Conducted a retrospective analysis comparing 21-day and 42-day dosing regimens of pembrolizumab.
• Monitored rates and severity of immune-related adverse effects
• Recorded steroid initiation and treatment discontinuation due to irAEs.
• Similar rates and severity of irAEs were observed between 21-day and 42-day dosing cohorts.
• No significant differences in steroid initiation for irAE management were found between dosing schedules.
• Permanent treatment discontinuation due to severe irAEs did not differ significantly by dosing schedule.